Clinical Trial

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-07; most recent amendment 2026-03-06.
Trial Details
NCT Number NCT06822881
Lead Sponsor Beijing GoBroad Hospital
Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Enrollment 27 participants
Start Date 2025-02-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10